HOME >> BIOLOGY >> NEWS
Eastern Europe urged to prepare now for growing threat of HIV resistance

Eastern Europe is warned to prepare for HIV drug resistance, a problem that is now being witnessed in patients in Poland after only five years of HIV treatment being available. Experts at an HIV congress in Warsaw heard today that FUZEON (enfuvirtide, formerly known as T-20), the latest weapon in the fight against HIV drug resistance, is a valuable tool to both patients and payers in the treatment of HIV, particularly when used earlier in pre-treated patients.

Eastern Europe urged to prepare for HIV resistance

John Bowis, OBE, Member of the European Parliament applauds the Ministry of Health in Poland for taking a pro-active lead in the fight against HIV and drug resistance: "The growing problem of HIV resistance is a serious issue which all members of the EU have a responsibility to manage. We must commit to share knowledge, particularly those countries more experienced in tackling the HIV epidemic, in an effort to provide a consistent standard of care and avert a potential healthcare crisis. We need to ensure that all European countries are benefiting from new treatments and are allocating vital resources where they will be of most value."

The increasing prevalence of HIV drug resistance means that many patients can no longer benefit from the first three classes of HIV drugs. Unlike existing anti-HIV drugs, which act inside the cell once it has been infected, FUZEON works on the outside actively blocking the fusion of the virus with cells of the human immune system (CD4 cells). Because of this very different mechanism of action, FUZEON is active against HIV strains that have become resistant to current therapies. FUZEON reduces HIV levels and increases CD4 cell counts even in patients with resistance to the three conventional classes of HIV drugs.

Improving survival in pre-treated patients carrying drug-resistant HIV

Reduction in HIV levels and improvements in CD4 cell counts have been shown to result in improved s
'"/>

Contact: Alexander Watson
Alexander.watson@ketchum.com
44-771-267-5990
Ketchum
27-Oct-2003


Page: 1 2 3

Related biology news :

1. Eastern lowland gorilla population plummets 70 percent since 1994
2. Eastern U.S. benefits from emissions trading by power plants
3. Environment in Eastern Europe benefits from Swedish funding
4. USGS Finds That Mysterious Arkansas Bald Eagle Disease Has Spread To Ducks In Eastern States
5. Clean Air Act Reduces Acid Rain In Eastern U.S.
6. Even Moderate Air Pollution Reaching Eastern Wilderness Decreases Mountain Hikers Lung Function
7. European common frog found to use novel mating strategy
8. Zoonotic diseases - European scientists unite to fight diseases
9. Second call for proposals for the European Young Investigator Award
10. Common call for action on European Research Council (ERC)
11. EURYI Award given for the first time to 25 young European researchers

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Eastern Europe urged prepare now for growing threat HIV resistance

(Date:10/29/2014)... who lose their hair as a consequence of chemotherapy ... improve the scalp cooling technology that prevents hair loss. ... being pioneered by global scalp cooling manufacturing company, Paxman ... biology department of the University of Huddersfield. , The ... who has a background in the pharmacology of cancer ...
(Date:10/29/2014)... research presented at the Society for Integrative Oncology ... for the first time that it is possible ... readily available nutritional supplement, AHCC. ... Smith, Pharm.D., associate professor in the Department of ... of Texas Health Science Center at Houston (UTHealth) ...
(Date:10/29/2014)... Many factors, both genetic and environmental, have been ... of schizophrenia. Some, such as a family history ... infection with Toxoplasma gondii , a parasite ... are still viewed with skepticism. , A new ... and epidemiology at the University of Pennsylvania,s School ...
Breaking Biology News(10 mins):New technology on the way to aid cancer suffers who lose their hair after chemotherapy 2HPV infections in women eradicated by AHCC, Japanese mushroom extract 2Penn vet professor investigates parasite-schizophrenia connection 2Penn vet professor investigates parasite-schizophrenia connection 3
(Date:10/27/2014)... and TORONTO , Oct. ... www.generex.com ) (OTCQB: GNBT) today announced two presentations ... triggered by its novel proprietary cancer immunotherapeutic AE37 ... breast cancer patients. The AE37 cancer vaccine is ... Express, Inc. ( www.antigenexpress.com ). The presentations are ...
(Date:10/27/2014)... Orlando, Florida (PRWEB) October 27, 2014 ... aims at reducing and eliminating several types of ... have not been achieved in over 30 years ... of Noah's Light Foundation, proves that one mom's ... was diagnosed just before Halloween trick-or-treating, and it’s ...
(Date:10/27/2014)... October 27, 2014 Investor-Edge has ... (NASDAQ: NBIX ), Insmed Inc. (NASDAQ: ... BCRX ), Dyax Corporation (NASDAQ: DYAX ), ... five companies can be accessed at: http://investor-edge.com/register ... Composite ended at 4,483.72, up 0.69%, the Dow Jones ...
(Date:10/25/2014)... 2014 ViaDerma, Inc ... devoted to bringing new products to market, is ... ViaDerma has developed an innovative, patent-pending dual carrier ... transfer of pharmaceutical active ingredients to penetrate the ... localized therapy. The transdermal delivery method also overcomes ...
Breaking Biology Technology:Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 4FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 2FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 3Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 2Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 3Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 4Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 5ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3
Cached News: